Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis

Clinical Infectious Diseases

Volumn 33, Issue 7, 2001, Pages 1069-1075

  Vazquez, Jose A ^a   Peng, Grace ^c   Sabel, Jack D ^a   Steele Moore, Lynn ^b   Schuman, Paula ^a   Holloway, William ^b   Neaton, James D ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CD4 ANTIGEN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VAGINA CANDIDIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0035478409     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322641     Document Type: Article

References (28)

1. Oral Candida albicans in HIV infection
2. Infection with the human immunodeficiency virus: Clinical manifestations and their relationship to immune deficiency. A report from the multicenter AIDS cohort study
3. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome
4. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection
5. Fungal infections in patients with AIDS and AIDS related complex
6. Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus
7. The growing problem of mycoses in patients infected with the human immunodeficiency virus
8. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS
9. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus
10. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: A randomized trial
11. Therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches
12. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
13. Weekly fluconazole in the prevention of mucosal candidiasis in women with HIV disease: A randomized, double-blind, placebo controlled study
14. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study
15. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: Randomized, double-blind, placebo-controlled study of 100 mg oral fluconazole daily
16. Change of causative organisms under antifungal treatment in immunosuppressed patients with HIV infections
17. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients: A double-blind placebo-controlled study
18. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
19. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy
20. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: The emergence of Candida glabrata?
21. Fluconazole-resistant Candida albicans after long-term suppressive therapy
22. Fluconazole-resistant Candida albicans
23. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis
24. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal candidiasis isolates from persons with advanced human immunodeficiency virus infection?
25. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection
26. Incidence of in-vitro antifungal cross resistance among fluconazole resistant C. albicans and T. glabrata isolates
27. Mechanisms and clinical impact of antifungal resistance